ChemomAb Ltd’s presentation at the AASLD The Liver Meeting® 2018 in San Francisco.

News Release 2018.11.14

SMC announced that ChemomAb Ltd. presented results of a study using STAM model at poster presentation at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2018 in San Francisco, November 9 -13.

Title: “CM101, a Novel CCL24 Blocking Antibody, Suppresses Hepatic Injury and Fibrosis in Experimental Models of Nash and Liver Fibrosis”